Sonalasense
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
99 Washington Ave Ste 1008, Albany, New ...Website
www.sonalasense.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Sonalasense
SonALAsense is a clinical-stage company developing sonodynamic therapy (SDT) as a first-in-class, noninvasive drug-device combination for the treatment of recurrent glioblastoma multiforme, diffuse intrinsic pontine gliomas, and other deadly cancers. SDT utilizes MR-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells.Explore more
Sonalasense Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sonalasense your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Sonalasense recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Sonalasense had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sonalasense has new funding data
Sonalasense, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Sonalasense has recently received funding, and reach out quickly before it becomes old news!
Check out if Sonalasense is spiking on competitors!
Product Launch: Get notified when Sonalasense launches new products
Congratulate Masked Content for being promoted to Masked Content at Sonalasense
Recommended Actions
Find VP level buyers at Sonalasense
Find 3 more new buyers
Compare Similar Companies to Sonalasense
Compare insights from companies similar to Sonalasense, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sonalasense is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sonalasense is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sonalasense.
Sonalasense Tech Stack
A closer look at the technologies used by Sonalasense
Most Recent Scoops
Event
Events
Funding
Project
Spending/Investment, Clinical Operations, Operations
New Hire
Executive Move
Open Position
Sonalasense News & Media
FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer
OAKLAND, Calif.--(BUSINESS WIRE)--SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development program of SONALA-001 in combination with the INSIGHTEC Exablate 4000 Type-2 Device for the treatment of patients with diffuse intrinsic pontine glioma (DIPG). This builds upon SONALA-001 also having received orphan drug designation inSonALAsense Welcomes Dr. Ely Benaim as Chief Medical Officer and Executive Vice President of Development
OAKLAND, Calif.--(BUSINESS WIRE)--SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), has appointed Ely Benaim, M.D., as Chief Medical Officer and Executive Vice President of Development. As a new member of the SonALAsense team, Dr. Benaim will play a crucial role in gaining FDA approval and commercializing SDT to treat aggressive brain tumors, such as diffuse intrinsic pontinSonALAsense Announces Completion of First Cohort in Phase 2 Study of SONALA-001 Sonodynamic Therapy for Recurrent Glioblastoma
OAKLAND, Calif.--(BUSINESS WIRE)-- #GBM--SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS), today announced that the first cohort in SDT-202 was fully enrolled. SDT-202 is an open-label, dose-escalation trial of SDT in recurrent glioblastoma (rGBM). The objectives of SDT-202, which builds upon a previous proof-of-concept (POC) trial conducted by Nader Sanai, MD, Chief ScientifSonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain Cancer
OAKLAND, Calif.--(BUSINESS WIRE)-- #braincancer--Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly pediatric brain cancer with a 2% five-year survival rate. To provide therapeutic options for patients and families, SonALAsense is partnering with clinicians at Children’s National Hospital, Ivy Brain Tumor Center at Barrow Neurological Institute, Phoenix Children’s Hospital and University of California San Francisco (UCSF) Medical Center to conduct a phase 1/2 clinical trial for sonodyn
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sonalasense
Sign Up For FreeTo access detailed company insights
SonALAsense is a clinical-stage company developing sonodynamic therapy (SDT) as a first-in-class, noninvasive drug-device combination for the treatment of recurrent glioblastoma multiforme, diffuse intrinsic pontine gliomas, and other deadly cancers. SDT utilizes MR-guided focused ultrasound (the device) in combination with aminolevulinic acid (a d... Read More
